Raymond James Downgrades Exact Sciences (EXAS) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Exact Sciences (EXAS) PT Lowered to $125 at Stifel
November 3, 2021 6:44 AM EDTStifel analyst Daniel Arias lowered the price target on Exact Sciences (NASDAQ: EXAS) to $125.00 (from $145.00) while maintaining a Buy rating.
The analyst commented, "EXAS's 3Q saw the company miss on Screening (Cologuard) revenues, and lower the outlook for 4Q - as... More
